Latest news with #Divi's
The Hindu
06-08-2025
- Business
- The Hindu
Divi's Q1 net up 27% YoY to ₹545 crore, slips sequentially
Active pharmaceutical ingredient (API) manufacturer Divi's Laboratories reported consolidated net profit for June quarter increased nearly 27% to ₹545 crore compared with ₹430 crore a year earlier. The net profit came on an almost 14% increase in the revenue from operations to ₹2,410 crore (₹2,118 crore). Sequentially, however, both the net profit and revenue from operations declined. The company, which specialises in generic APIs, custom synthesis and nutraceuticals, had for the March quarter posted ₹662 crore net profit and ₹2,585 crore revenue from operations. Divi's shares on Wednesday closed 4.29% lower to ₹6,134.25 each on the BSE.
Mint
06-08-2025
- Business
- Mint
Divi's Laboratories' June-quarter profit, margin miss estimates
Contract development and manufacturing organization (CDMO) Divi's Laboratories Ltd's June-quarter earnings missed estimates due to pricing pressure on its generics business. While the Hyderabad-based drugmaker's revenue from operations rose 13.7% year-on-year to ₹ 2,410 crore, its net profit jumped 26.7% to ₹ 545 crore. On a standalone basis, its net profit stood at ₹ 557 crore in the first quarter of 2025-26. A poll of 18 brokerages by Bloomberg had pegged the revenue at ₹ 2,462 crore and net profit at ₹ 582.7 crore. The company's Ebitda increased 17.2% on-year to ₹ 729 crore. Its Ebitda margin expanded slightly to 30.25% as against 29.37% a year ago. Ebitda is earnings before interest, taxes, depreciation and amortization. Brokerages Kotak Securities and Nuvama had pegged the company's Ebitda margin to expand to 33-34% in the quarter under review. Its generics business generated 47% of its overall revenue, and the custom synthesis business generated the rest. Divi's manufactures drugs for generic players as well as innovators. Custom synthesis refers to the production of specific chemical compounds, such as novel APIs or intermediates, tailored to a client's needs. APIs are core components of a medicine responsible for making its treatment effective. Persistent pricing pressure in global markets, particularly the US has affected generic drugmakers and weighed on Divi's as well. The company's management, however, told investors in an earnings call on Wednesday that the firm continues to be resilient on account of its strong backward integration. Divi's has seen increased interest from global innovators as well, the company's management said. As innovators look to derisk and diversify supply chains away from China, Indian CDMO giants like Divi's are poised to gain. The company has seen a steady increase in requests for proposals. In the last quarter of 2024-25, the company announced a long-term manufacturing and supply agreement with a leading global pharmaceutical company for which it is investing ₹ 650-750 crore. In January, it commenced commercial operations at Unit 3 of its Kakinada facility. This year, the company is planning to execute three capex programmes with an estimated expenditure of ₹ 2,000 crore, chief executive Kiran Divi told investors. Divi's Laboratories shares closed at ₹ 6,183 on National Stock Exchange on Wednesday, down 3.53% as the company's earnings missed estimates.
Business Recorder
06-08-2025
- Business
- Business Recorder
Indian drugmaker Divi's misses June-quarter profit view on weak US pricing
India's Divi's Laboratories reported first-quarter profit below estimates on Wednesday, as manufacturers producing generic drugs continued to be negatively impacted by pricing pressures in the key U.S. market, sending shares down 3.3%. The Hyderabad-based company's consolidated net profit rose 26.7% to 5.45 billion rupees ($62 million) for the quarter ended June 30. Analysts, on average, had expected 5.75 billion rupees, as per data compiled by LSEG. Indian generic drugmakers, which get a significant chunk of their revenue from the U.S., have been grappling with weak pricing amid stiff competition in the region. Divi's, one of India's largest manufacturers of active pharmaceutical ingredients (API), has flagged pricing pressure and high competition in its generics business in global markets, adding that it aims to increase its market share by launching molecules as they get off patent. APIs are key chemical components in a drug that produce the intended therapeutic effects. Divi's exports to more than 100 countries, with the U.S. and Europe being its core markets The company's shares were down 2.5% before the news, in tandem with the rest of the pharma stocks on U.S. President Donald Trump's potential tariff threat. India's Pidilite posts higher quarterly profit on strong demand; announces bonus issue The drugmaker's peers Cipla and Dr Reddy's also reported subdued June-quarter sales in the U.S. Revenue from operations for Divi's rose 14% to 24.10 billion rupees, also missing analysts' estimates of 24.56 billion rupees. The company is banking on demand from diabetes and weight-loss drugs manufacturers such as Eli Lilly, who cater to skyrocketing customer demand for the drug in global markets.
Business Upturn
06-08-2025
- Business
- Business Upturn
Divi's Laboratories shares drop 3% as Q1 misses estimates
By Aman Shukla Published on August 6, 2025, 12:11 IST Divi's Laboratories shares came under pressure, falling more than 3% after the company's Q1 FY26 results fell short of street expectations. As of 12:12 PM, the shares were trading 2.74% lower at Rs 6,233.50. For the quarter ended June 30, 2025, Divi's posted a net profit of ₹545 crore, below the CNBC-TV18 poll estimate of ₹573 crore, though it marked a 26.7% rise from ₹430 crore in Q1 FY25. Revenue from operations came in at ₹2,410 crore, up 13.8% YoY, but also shy of the expected ₹2,437 crore. On the operational front, EBITDA stood at ₹756 crore, registering a 16.3% YoY growth, but again missed estimates pegged at ₹794.8 crore. EBITDA margin improved to 31.4% from 30.7% a year ago, though fell short of the 32.6% projection. Sequentially, however, numbers were softer — revenue declined 6.8%, and net profit fell nearly 18% versus Q4 FY25. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Time of India
06-08-2025
- Business
- Time of India
Stocks in news: Bajaj Auto, Trent, Britannia, Sandur Manganese, Airtel
Markets experienced a downturn, reversing Monday's gains. Several companies, including Bajaj Auto, Trent, Divi's, and Hero MotoCorp, are set to announce their Q1 results. Britannia reported a 3% increase in consolidated net profit, while Bharti Airtel saw a substantial 43% rise. Societe Generale acquired a significant stake in Paytm as Ant Group exited. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Markets reversed Monday's gains and lost nearly half a percent, continuing the prevailing corrective trend. In today's trade, shares of Bajaj Auto Airtel among others will be in focus due to various news developments and first quarter of Bajaj Auto, Trent, Divi's and Hero MotoCorp will be in focus as the companies will announce their first quarter stock Sandur Manganese informed the exchanges that its board will meet on Friday to consider a proposal for issue of bonus sharesBritannia reported a 3% growth in its Q1FY26 consolidated net profit at Rs 521 crore versus Rs 506 crore in the year ago banking behemoth Societe Generale bought over 67 lakh shares worth Rs 720 crore in One 97 Communications via a couple of bulk deals on Tuesday where Ant Group made a complete exit. Bharti Hexacom reported a 16% quarter-on-quarter decline in net profit at Rs 392 crore for Gas posted a healthy set of numbers for the first quarter of financial year 2025–26 with net profit rising 14% to Rs 328 croreBharti Airtel on Tuesday reported a 43% growth in its Q1 consolidated net profit to Rs 5,948 crore compared to Rs 4,159 crore in the year ago period.
